Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 69.18 Million EUR | 7.6% |
| 2022 | 66.31 Million EUR | 61.82% |
| 2021 | 40.98 Million EUR | -49.92% |
| 2020 | 65.16 Million EUR | 1916.56% |
| 2019 | 4.05 Million EUR | 414.97% |
| 2018 | -83 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 21.55 Million EUR | 152.54% |
| 2024 Q2 | 21.62 Million EUR | 5.41% |
| 2024 Q3 | 18.41 Million EUR | -18.93% |
| 2023 Q4 | 8.53 Million EUR | -53.08% |
| 2023 Q2 | 18.41 Million EUR | -28.04% |
| 2023 Q3 | 18.19 Million EUR | -1.22% |
| 2023 Q1 | 25.59 Million EUR | 419.46% |
| 2023 FY | - EUR | 7.6% |
| 2022 Q4 | -8.01 Million EUR | -151.34% |
| 2022 FY | - EUR | 61.82% |
| 2022 Q3 | 15.6 Million EUR | 9.7% |
| 2022 Q2 | 14.22 Million EUR | -18.17% |
| 2022 Q1 | 17.38 Million EUR | 171.58% |
| 2021 Q2 | 5.66 Million EUR | -63.68% |
| 2021 FY | - EUR | -49.92% |
| 2021 Q4 | 6.4 Million EUR | -28.54% |
| 2021 Q3 | 8.95 Million EUR | 58.06% |
| 2021 Q1 | 15.6 Million EUR | -79.24% |
| 2020 Q1 | 1.49 Million EUR | 0.0% |
| 2020 Q3 | 5.44 Million EUR | 2049.82% |
| 2020 Q2 | -279 Thousand EUR | -118.61% |
| 2020 Q4 | 75.17 Million EUR | 1281.84% |
| 2020 FY | - EUR | 1916.56% |
| 2019 FY | - EUR | 414.97% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AroCell AB (publ) | -13.75 Million SEK | 602.842% |
| Devyser Diagnostics AB (publ) | -43.8 Million SEK | 257.959% |
| Immunovia AB (publ) | -166.55 Million SEK | 141.538% |
| Prostatype Genomics AB (publ) | -38.02 Million SEK | 281.973% |
| SenzaGen AB | -13.53 Million SEK | 611.126% |
| Spermosens AB | -10.7 Million SEK | 746.357% |